Drug maker Hetero has received approval for the generic version of Sofosbuvir and Velpatasvir combination drug from the Drug Controller-General of India.
The approved drug is a generic of Gilead’s Epclusa brand and is indicated for the treatment of chronic Hepatitis C genotype 1 to 6, the Hyderabad-based Hetero said in a release issued here on Friday.
It will be distributed and marketed in the domestic market under the brand 'Velasof’ by Hetero Healthcare.
"This product will be launched under a non-exclusive agreement with Gilead Science Inc, which allows it to manufacture and sell generic versions of its chronic Hepatitis C medicines in 101 developing countries,’’ the company said.